PSNL News and Press, Personalis Inc. From 05/03/23

2023-05-03 16:40:37 ET Personalis press release ( NASDAQ: PSNL ): Q1 GAAP EPS of -$0.61 misses by $0.05 . Revenue of $18.9M (+24.1% Y/Y) beats by $1.55M . Cash, cash equivalents, and short-term investments of $148.9 million as of March 31, 2023 Personalis...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter ended March 31, 2023 and provided recent business highlights. Recent Business Updates Announced a collaboration with Cancer Research UK, Univ...

Personalis, Inc. (Nasdaq: PSNL) today announced it has partnered with the Academic Breast Cancer Consortium (ABRCC) and Criterium to carry out a prospective clinical trial, B-STRONGER-1 (Breast Cancer-Minimal Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phas...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its first quarter 2023 financial results on Wednesday, May 3, 2023. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m....

2023-04-17 13:11:50 ET Summary Today, we put diagnostic firm Personalis, Inc. back in the spotlight as the shares go for less than the company's net cash on the balance sheet. The company has brought in a new CEO and announced significant cost saving measures. An updated inves...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19 at 3:00 p.m. Eastern Time. About Personalis, Inc. At ...

Personalis’ NeXT Personal® liquid biopsy assay will be deployed in a collaboration for TRACERx to assess approaches for earlier lung cancer recurrence post-surgery and for relapse Personalis, Inc. (Nasdaq: PSNL), Cancer Research UK’s Cancer Research Horizons, Universi...

New findings reinforce potential of company’s highly-sensitive MRD offerings for earlier recurrence detection and therapy response monitoring Personalis, Inc. (Nasdaq: PSNL) today announced it is presenting new research data as scientific posters at the American Association for C...

Company Will Explore Use of NeXT Personal® in AstraZeneca Trial Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it will continue its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), a global science-led biopharmaceutical c...

Personalis ( NASDAQ: PSNL ) on Thursday said the company appointed Christopher Hall as CEO and a member of the board, effective immediately. Hall will become CEO in addition to his role as president. Hall joined Personalis in October 2022 and became presiden...